Zobrazeno 1 - 10
of 92
pro vyhledávání: '"Ka, K. A"'
Publikováno v:
Journal of Clinical Sport Psychology; Jun2024, Vol. 18 Issue 2, p270-285, 16p
Publikováno v:
In Current Opinion in Physiology October 2023 35
Autor:
Mak, Joyce W. Y., Sun, Yang, Limsrivilai, Julajak, Abdullah, Murdani, Kaibullayeva, Jamilya, Balderramo, Domingo, Vergara, Beatriz I., Paudel, Mukesh S., Banerjee, Rupa, Hilmi, Ida, Ali, Raja A. R., Wei, Shu C., Ng, Ka K., Altuwaijri, Mansour, Kelly, Paul, Yamamoto-Furusho, Jesus K., Kotze, Paulo G., Ahuja, Vineet, Chong, Vui H., Dao, Hang V., Abbey, Yvonne, Ching, Jessica Y. L., Ho, Agnes, Chan, Alicia K. W., Bernstein, Charles N., Gearry, Richard B., Abreu, Maria, Rubin, David T., Dotan, Iris, Hracs, Lindsay, Kaplan, Gilaad G., Ng, Siew C.
Background There is a rapid increase in the incidence of inflammatory bowel diseases (IBD) in newly industrialized countries, yet epidemiological data is incomplete. We herein report the methodology adopted to study the incidence of IBD in newly indu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_______217::26c65a82d244e9f149e6d94a3da55427
https://hdl.handle.net/1993/37376
https://hdl.handle.net/1993/37376
Autor:
Kin L. Wong, Zhengdong Li, Felix Ma, Dong Wang, Nan Song, Chi H. Chong, Ka K. Luk, Shui O. Leung
Publikováno v:
The Journal of Immunology. 208:2726-2737
SM03, an anti-CD22 recombinant IgG1 mAb, is currently in a phase III clinical trial for the treatment of rheumatoid arthritis (NCT04312815). SM03 showed good safety and efficacy in phase I systemic lupus erythematosus and phase II moderate to severe
Publikováno v:
In International Journal of Radiation Oncology, Biology, Physics 1 October 2024 120(2) Supplement:S75-S75
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Kin L, Wong, Zhengdong, Li, Felix, Ma, Dong, Wang, Nan, Song, Chi H, Chong, Ka K, Luk, Shui O, Leung
Publikováno v:
Journal of immunology (Baltimore, Md. : 1950). 208(12)
SM03, an anti-CD22 recombinant IgG1 mAb, is currently in a phase III clinical trial for the treatment of rheumatoid arthritis (NCT04312815). SM03 showed good safety and efficacy in phase I systemic lupus erythematosus and phase II moderate to severe
Recently, in a series of papers "simple" versions of direct-injective and direct-projective modules have been investigated. These modules are termed as "simple-direct-injective" and "simple-direct-projective", respectively. In this paper, we give a c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::17fb83e10ada030296305dd3f4053cac
Publikováno v:
Acta Médica Portuguesa, Vol 19, Iss 1 (2006)
To characterize compulsory treatments done in Macao in the five years after its implementation in 1999.A descriptive and retrospective study was done consulting the clinical files of persons that did compulsory treatments in Macao in the five years a
Externí odkaz:
https://doaj.org/article/246eec4267dc43f08ecdb1f2f657a5d0
Publikováno v:
IOP Conference Series: Materials Science & Engineering; 2021, Vol. 1199 Issue 1, p1-13, 13p